Some patients with UC may not achieve an adequate primary response to treatment. Omvoh® is the first IL-23p19 inhibitor offering flexible dosing in label, allowing patients with UC, even those who are difficult to treat, the opportunity to stay on course¹.
Indication
Omvoh (mirikizumab) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.
For full information see Omvoh physician leaflet approved by the Israeli MOH.
References
1. D'Haens G, et al. N Engl J Med. 2023;388(26):2444–2455.
הירשמו לקבלת עדכונים בנושאים שעלו בכתבה
תגובות אחרונות